Zura Bio Limited ZURA
4.09 USD +0.37 (+9.95%)
At closeNov 6, 2026, 5:45 PM EST
4.15 +0.06 +1.47%
After hours · Nov 6, 5:45 PM ET
3.76 Day range 4.25
3.36 52-week range 7.04
- YTD
- -21.95%
- 1 year
- +17.53%
- Market cap
- 393.97M
- EPS (ttm)
- -1.11
- Shares out
- 65.29M
- Forward P/E
- -3.22
- YTD return
- -21.95%
- 1-year return
- +17.53%
- Volume
- 3.01M
- Avg volume
- 2.82M
- Open
- 3.80
- Previous close
- 3.72
- Day's range
- 3.76 – 4.25
- 52-week range
- 3.36 – 7.04
- Beta
- 0.14
- Analysts
- Strong Buy
- Price target
- 14.29 (+249.3%)
- Earnings date
- Aug 13, 2024
5D +0.08 (+2.00%)
Key statistics
- Enterprise value
- -21.57M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 1.02
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -18.87M
- Total cash
- 188.22M
- Total debt
- 0
- Return on equity
- -36.85%
- Short % of float
- 9.54%
- 50-day average
- 3.61
- 200-day average
- 3.76
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 14.29 +249.3% upside
Now 4.09
- Target (low)
- 5.00
- Target (mean)
- 14.29
- Target (high)
- 26.00
Ratings (0m) 8 7 buy · 1 hold · 0 sell
- Strong buy1
- Buy6
- Hold1
- Sell0
- Strong sell0
Next earnings
Aug 13, 2024
Expected Aug 13, 2024. Consensus EPS estimate 0.00.
Financials — quick view
ZURA Revenue — quarterly 0
ZURA Net income — quarterly -25.82M
ZURA EPS — quarterly -0.20
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 7, 2024 | Sep 1, 2024 | -0.14 | -0.26 | -0.12 | -85.71% |
| Aug 13, 2024 | Jun 1, 2024 | -0.13 | -0.17 | -0.04 | -30.77% |
| Aug 13, 2024 | Jun 1, 2024 | -0.13 | — | — | — |
| May 9, 2024 | Mar 1, 2024 | -0.23 | — | — | — |
| May 9, 2024 | Mar 1, 2024 | -0.23 | -0.02 | +0.21 | +91.30% |
| Mar 26, 2024 | Dec 1, 2023 | -0.25 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 11, 2024 | Cantor Fitzgerald | reit | Overweight | Overweight |
| Nov 18, 2024 | HC Wainwright & Co. | reit | Neutral | Neutral |
| Nov 11, 2024 | HC Wainwright & Co. | reit | Neutral | Neutral |
| Nov 8, 2024 | Chardan Capital | main | Buy | Buy |
| Nov 4, 2024 | Leerink Partners | init | — | Outperform |
| Oct 21, 2024 | HC Wainwright & Co. | reit | Neutral | Neutral |
About Zura Bio Limited
Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in Henderson, Nevada.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- zurabio.com
News
12 Health Care Stocks Moving In Tuesday's Intraday Session 
Zura Bio Q3 EPS $(0.20), Inline 
BKV, Lamb Weston, Penguin Solutions And Other Big Stocks Moving Higher On Wednesday 
Wedbush Maintains Outperform on Zura Bio, Raises Price Target to $22 
Guggenheim Maintains Buy on Zura Bio, Raises Price Target to $20 - Zura Bio Q2 EPS $(0.21) Misses $(0.20) Estimate
Analyst Sees Multi-Billion-Dollar Sales Potential for Zura Bio’s Lead Therapy - Zura Bio Completes Enrollment In Phase 2 TibuSHIELD Trial of Tibulizumab in Adults With HS
Zura Bio Q1 EPS $(0.22) Misses $(0.18) Estimate - Zura Bio Announces Separation From CFO Eric Hyllengren; Marlyn Mathew Named Principal Accounting And Principal Financial Officer
Your note
Sign in to keep a note on ZURA — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CABELL CHRISTOPHER H | Officer | Stock Award(Grant) | May 17, 2023 | 162,060 |
| DAVIS KIMBERLY ANN | Officer | Stock Award(Grant) | May 17, 2023 | 492,381 |
| HOWELL MICHAEL | Officer | Stock Award(Grant) | Apr 21, 2024 | 0 |
| MUNSHI AMIT D | Director | Stock Award(Grant) | Apr 21, 2024 | 777,384 |
| NISTALA KIRAN | Officer | Stock Award(Grant) | Apr 21, 2024 | 3,195 |
| PLOOS VAN AMSTEL ARNOUT | Director | Purchase | May 16, 2024 | 100,000 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Suvretta Capital Management, LLC | 7.44% | 4,860,939 | 11.57M | Sep 29, 2024 |
| Adar1 Capital Management, LLC | 5.77% | 3,770,649 | 8.97M | Sep 29, 2024 |
| Deep Track Capital, Lp | 5.03% | 3,283,783 | 7.82M | Sep 29, 2024 |
| Great Point Partners LLC | 5.00% | 3,263,672 | 7.77M | Sep 29, 2024 |
| RA Capital Management, L.P. | 4.93% | 3,217,503 | 7.66M | Sep 29, 2024 |
| Braidwell LP | 3.79% | 2,472,806 | 5.89M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| iShares Russell 2000 ETF | 1.54% | 1,006,940 | 2.40M | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 0.73% | 479,136 | 1.14M | Sep 29, 2024 |
| iShares Russell 2000 Growth ETF | 0.63% | 408,101 | 971.28K | Oct 30, 2024 |
| Fidelity Small Cap Index Fund | 0.31% | 203,558 | 484.47K | Aug 30, 2024 |
| Fidelity Extended Market Index Fund | 0.31% | 205,182 | 488.33K | Oct 30, 2024 |
| Schwab Strategic Tr-Schwab U.S. Small Cap ETF | 0.20% | 132,537 | 315.44K | Aug 30, 2024 |